Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
9 papers
Recent·Most cited
A. K. Najumudeen, S. K. Fey, L. M. Millet, C. A. Ford, K. Gilroy, N. Gunduz, R. A. Ridgway, E. Anderson, D. Strathdee, W. Clark, C. Nixon, J. P. Morton, A. D. Campbell, O. J. Sansom
This study shows that wild-type KRAS suppresses tumour growth and metastasis in KRAS mutant colorectal cancer while enhancing resistance to MEK inhibition.
bioRxiv · Aug 29, 2023 · PreprintCancer Biology
S. K. Fey, A. K. Najumudeen, C. A. Ford, K. Gilroy, R. Upstill-Goddard, W. Clark, C. Nixon, D. K. Chang, S. T. Barry, J. P. Morton, A. D. Campbell, O. J. Sansom
This study shows that loss of wild-type Kras enhances oncogenic Kras signaling and promotes pancreatic ductal adenocarcinoma, while also increasing sensitivity to MEK1/2 inhibitors.
bioRxiv · Aug 29, 2023 · PreprintCancer Biology
J. Vande Voorde, A. K. Najumudeen, R. T. Steven, C. J. Nikula, A. Dexter, L. B. Zeiger, E. A. Elia, A. Nassif, A. Gonzalez-Fernandez, T. Murta, M. Gillespie, C. A. Ford, T. R. M. Lannagan, N. Vlahov, R. A. Ridgway, , O. J. Sansom
This study uses metabolomics to stratify colorectal cancer tissues and identifies adenosylhomocysteinase as a potential therapeutic target.
bioRxiv · Mar 12, 2023Cancer Biology
J. Leslie, J. B. G. Mackey, T. Jamieson, E. Ramon-Gil, T. M. Drake, F. Fercoq, W. Clark, K. Gilroy, A. Hedley, C. Nixon, S. Luli, M. Laszczewska, R. Pinyol, R. Esteban-Fabro, C. E. Willoughby, , Carlin
This study shows that combining CXCR2 inhibition with anti-PD1 therapy enhances immunotherapy response in NASH-HCC by reprogramming tumor-associated neutrophils.
bioRxiv · Feb 24, 2022Cancer Biology
C. Kiourtis, A. Wilczynska, C. Nixon, W. Clark, S. May, T. G. Bird
This study investigates the short-term off-target effects of AAV8 vectors in mice, finding minimal physiological and transcriptomic impacts with no evidence of liver injury.
bioRxiv · Feb 19, 2021 · PreprintCell Biology
S. May, M. Mueller, C. R. Livingstone, G. Skalka, C. Nixon, A. Hedley, R. Shaw, W. Clark, T. M. Drake, C. Kiourtis, A. S. Rocha, O. J. Sansom, T. G. Bird
This study re-evaluates lineage tracing in Axin2CreERT2 mice and reports absence of pericentral hepatocyte expansion and altered Wnt pathway physiology.
bioRxiv · Dec 9, 2020 · PreprintCell Biology
R. S. Martinez, M. J. Salji, L. Rushworth, C. Ntala, G. Rodriguez Blanco, A. Hedley, W. Clark, P. Peixoto, E. Hervouet, E. Renaude, S. H. Kung, L. C. Galbraith, C. Nixon, S. Lilla, G. M. MacKay, , H. Y. Leung
This study identifies SLFN5 as an AR-regulated biomarker in CRPC that promotes tumour growth by regulating LAT1-mediated mTOR activation.
bioRxiv · Sep 17, 2020 · PreprintCancer Biology
A.-L. Latif, A. Newcombe, S. Li, K. Gilroy, N. Robertson, X. Lei, H. Stewart, J. Cole, M. T. Terradas, L. Rishi, L. McGarry, C. McKeeve, C. Reid, W. Clark, J. Campos, , P. D. Adams
This study shows that combining MDM2 inhibitors and BET inhibitors synergistically kills AML cells by enhancing p53 activation through BRD4's repressive function.
bioRxiv · Sep 16, 2020Cell Biology
B. Kruspig, T. Monteverde, S. Neidler, A. Hock, E. Kerr, C. Nixon, W. Clark, A. Hedley, C. Dick, K. Vousden, C. Martins, D. Murphy
This study shows that the ERBB network is required for KRAS-driven lung tumorigenesis and that inhibiting it enhances MEK inhibitor efficacy in treating such cancers.
bioRxiv · Apr 9, 2018Cancer Biology